{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:38:59Z","timestamp":1781653139905,"version":"3.54.5"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>(1) Background: To explore the impact of the degree of inflammation on voriconazole exposure in critically ill patients affected by COVID-associated pulmonary aspergillosis (CAPA); (2) Methods: Critically ill patients receiving TDM-guided voriconazole for the management of proven or probable CAPA between January 2021 and December 2022 were included. The concentration\/dose ratio (C\/D) was used as a surrogate marker of voriconazole total clearance. A receiving operating characteristic (ROC) curve analysis was performed by using C-reactive protein (CRP) or procalcitonin (PCT) values as the test variable and voriconazole C\/D ratio &gt; 0.375 (equivalent to a trough concentration [Cmin] value of 3 mg\/L normalized to the maintenance dose of 8 mg\/kg\/day) as the state variable. Area under the curve (AUC) and 95% confidence interval (CI) were calculated; (3) Results: Overall, 50 patients were included. The median average voriconazole Cmin was 2.47 (1.75\u20133.33) mg\/L. The median (IQR) voriconazole concentration\/dose ratio (C\/D) was 0.29 (0.14\u20130.46). A CRP value &gt; 11.46 mg\/dL was associated with the achievement of voriconazole Cmin &gt; 3 mg\/L, with an AUC of 0.667 (95% CI 0.593\u20130.735; p &lt; 0.001). A PCT value &gt; 0.3 ng\/mL was associated with the attainment of voriconazole Cmin &gt; 3 mg\/L (AUC 0.651; 95% CI 0.572\u20130.725; p = 0.0015). (4) Conclusions: Our findings suggest that in critically ill patients with CAPA, CRP and PCT values above the identified thresholds may cause the downregulation of voriconazole metabolism and favor voriconazole overexposure, leading to potentially toxic concentrations.<\/jats:p>","DOI":"10.3390\/antibiotics12040764","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T03:14:09Z","timestamp":1681701249000},"page":"764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"},{"name":"Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Fornaro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeno","family":"Pasquini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-3675","authenticated-orcid":false,"given":"Andrea","family":"Zanoni","sequence":"additional","affiliation":[{"name":"Division of Anesthesiology, Department of Anesthesia and Intensive Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"},{"name":"Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":false,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"},{"name":"Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10096-020-04142-w","article-title":"Nosocomial Infections Associated to COVID-19 in the Intensive Care Unit: Clinical Characteristics and Outcome","volume":"40","author":"Bardi","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jac\/dkaa530","article-title":"Predictors of Hospital-Acquired Bacterial and Fungal Superinfections in COVID-19: A Prospective Observational Study","volume":"76","author":"Falcone","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cmi.2020.10.021","article-title":"Secondary Infections in Patients Hospitalized with COVID-19: Incidence and Predictive Factors","volume":"27","author":"Ripa","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jointm.2021.07.001","article-title":"COVID-19-Associated Pulmonary Aspergillosis (CAPA)","volume":"1","author":"Dimopoulos","year":"2021","journal-title":"J. Intensive Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Reizine, F., Pinceaux, K., Lederlin, M., Autier, B., Guegan, H., Gacouin, A., Luque-Paz, D., Boglione-Kerrien, C., Bacle, A., and Le Dar\u00e9, B. (2021). Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?. J. Fungi, 7.","DOI":"10.21203\/rs.3.rs-331976\/v1"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","article-title":"Fungal Infections in Mechanically Ventilated Patients with COVID-19 during the First Wave: The French Multicentre MYCOVID Study","volume":"10","author":"Gangneux","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/mmy\/myaa078","article-title":"Pulmonary Aspergillosis in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19)","volume":"59","author":"Dupont","year":"2021","journal-title":"Med. Mycol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial Therapeutic Drug Monitoring in Critically Ill Adult Patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic Drug Monitoring of Anti-Infective Agents in Critically Ill Patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1128\/AAC.00251-13","article-title":"Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies","volume":"57","author":"Hoenigl","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1111\/bcp.15495","article-title":"Effects of Inflammation on Voriconazole Levels: A Systematic Review","volume":"88","author":"Li","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/AAC.04789-14","article-title":"Influence of Inflammation on Voriconazole Metabolism","volume":"59","author":"Span","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/AAC.02830-15","article-title":"Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations","volume":"60","author":"Span","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole Metabolism Is Influenced by Severe Inflammation: A Prospective Study","volume":"72","author":"Veringa","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/Pharmacodynamic Profile of Voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin. Pharm."},{"key":"ref_19","first-page":"10600280211047864","article-title":"Inflammation Suppresses Patients\u2019 Ability to Metabolize Cytochrome P450 Substrate Drugs","volume":"56","author":"White","year":"2021","journal-title":"Ann. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40262-022-01173-8","article-title":"The Cytokine Release Syndrome and\/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of This Drug\u2013Disease Interaction Under Different Clinical Conditions","volume":"61","author":"Gatti","year":"2022","journal-title":"Clin. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough Concentration of Voriconazole and Its Relationship with Efficacy and Safety: A Systematic Review and Meta-Analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jiac.2020.11.014","article-title":"Optimal Trough Concentration of Voriconazole with Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-Analysis","volume":"27","author":"Hanai","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and Safety of Voriconazole and CYP2C19 Polymorphism for Optimised Dosage Regimens in Patients with Invasive Fungal Infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/myc.13293","article-title":"The Influence of CYP2C19 Polymorphisms on Voriconazole Trough Concentrations: Systematic Review and Meta-Analysis","volume":"64","author":"Zhang","year":"2021","journal-title":"Mycoses"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40780-016-0044-9","article-title":"A Retrospective Analysis of Patient-Specific Factors on Voriconazole Clearance","volume":"2","author":"Dote","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/fcp.12422","article-title":"Inflammation Is a Potential Risk Factor of Voriconazole Overdose in Hematological Patients","volume":"33","author":"Truffot","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106078","DOI":"10.1016\/j.intimp.2019.106078","article-title":"Therapeutic Drug Monitoring and Safety of Voriconazole in Elderly Patients","volume":"78","author":"Cheng","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/jcpt.12817","article-title":"Impact of Voriconazole Plasma Concentrations on Treatment Response in Critically Ill Patients","volume":"44","author":"Ruiz","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13054-021-03568-8","article-title":"Toward the Personalized and Integrative Management of Voriconazole Dosing during COVID-19-Associated Pulmonary Aspergillosis","volume":"25","author":"Reizine","year":"2021","journal-title":"Crit. Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bcp.14953","article-title":"Challenge in Treating COVID-19 Associate Pulmonary Aspergillosis: Supratherapeutic Voriconazole Levels","volume":"88","author":"Kara","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40263-021-00811-2","article-title":"Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies","volume":"35","author":"Gatti","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13054-022-04050-9","article-title":"Expert Clinical Pharmacological Advice May Make an Antimicrobial TDM Program for Emerging Candidates More Clinically Useful in Tailoring Therapy of Critically Ill Patients","volume":"26","author":"Gatti","year":"2022","journal-title":"Crit. Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and Managing COVID-19-Associated Pulmonary Aspergillosis: The 2020 ECMM\/ISHAM Consensus Criteria for Research and Clinical Guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","unstructured":"(2023, March 20). European Medicines Agency\u2014EMA Guideline on the Investigation of Drug Interactions 2015. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf."},{"key":"ref_35","unstructured":"(2023, March 20). Chromsystems Instruments & Chemicals GmbH. MassTox TDM Series A. 2022. Available online: https:\/\/chromsystems.com\/masstox-tdm-series-a."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of Voriconazole Therapeutic Drug Monitoring: A Meta-Analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:16:48Z","timestamp":1760123808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,16]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["antibiotics12040764"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12040764","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,16]]}}}